A Phase 3 interventional study of Genotropin (PN-180,307) Somatropin and Control-no treatment in Infant, Small for Gestational Age, sponsored by Pfizer. Completed at 17 sites in 9 countries. Open to participants aged 19 Months to 29 Months. Per ClinicalTrials.gov, last updated 2014-11-04.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Caucasian male or female subjects aged between 19-29 months at Screening Visit 1.
Born SGA (birth length and/or weight \<-2 SD for gestational age, using country-specific standards).
Height below -2.5 SD at screening (19-29 months of age). At least one measurement of length between 12 and 18 months of age. Normal karyotype in girls to exclude Turners syndrome.
Exclusion Criteria:
Severe Intra-Uterine Growth Retardation (IUGR) (birth length below - 4 SD for gestational age), if associated with dysmorphic features.
Severe prematurity (Gestational Age (GA) \<32 weeks of gestation). Ongoing catch-up growth (defined as growth velocity SDS at inclusion >0) based on at least 4 months measurement interval).
Severe familial short stature defined as: Father's height below 155 cm or mother's height below 145 cm.
Defined neurological defects and/or severe neurodevelopmental delay.
The active treatment arm
Drug: Genotropin (PN-180,307) Somatropin
Control
Drug: Control-no treatment
Injectable Genotropin
Control-no treatment
Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.
Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.
Time frame: Baseline and Month 24
Change From Baseline in Growth Velocity SDS at Month 24.
The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.
Time frame: Baseline and Month 24
Change From Baseline in Height SDS at Month 12.
Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.
Time frame: Baseline and Month 12
Change From Baseline in Growth Velocity SDS at Month 12.
The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.
Time frame: Baseline and Month 12
Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.
The Bayley Scale of Infant Development (BSID-II) measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the mental raw score which was used to calculate the MDI score. Possible MDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.
Time frame: Baseline and Month 12
Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.
BSID-II measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the psychomotor raw score which was used to calculate the PDI score. Possible PDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.
Time frame: Baseline and Month 12
Head Circumference SDS at Months 3, 6, 12, 18 and 24.
Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/ Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.
Time frame: Months 3, 6, 12, 18 and 24
Change From Baseline in Head Circumference SDS at Months 3, 6, 12, 18 and 24.
Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.
Time frame: Baseline, Months 3, 6, 12, 18 and 24.
Change From Baseline in Body Weight at Months 3, 6, 12, 18, and 24.
Body weight was measured at all the relevant visits. The change from Baseline in body weight was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.
Time frame: Baseline, Months 3, 6, 12, 18, and 24
Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 12, 18, and 24.
Body mass index was calculated for all visits by means of the following formula: BMI (kg/m2) = Weight (kg)/(Height\[m\])2. The change from Baseline BMI was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.
Time frame: Baseline, Months 3, 6, 12, 18, and 24
This randomized controlled trial enrolled small for gestational age (SGA) children at 16 centers in 8 countries. In total, 52 participants were screened for the study, of these, 9 participants were considered screen failures. The remaining 43 participants were randomized to receive either study drug (Genotropin®) or were not treated (Control).
| Milestone | Genotropin® | Control |
|---|---|---|
| Started | 21 | 22 |
| Completed | 19 | 20 |
| Not completed | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 1 | 0 |
Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. | 1.63 ± 0.13 | 0.43 ± 0.13 |
The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Growth Velocity SDS at Month 24. | 0.74 ± 0.57 | -0.03 ± 0.57 |
Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Height SDS at Month 12. | 1.03 ± 0.12 | 0.14 ± 0.12 |
The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Growth Velocity SDS at Month 12. | 1.65 ± 0.56 | -1.59 ± 0.56 |
The Bayley Scale of Infant Development (BSID-II) measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the mental raw score which was used to calculate the MDI score. Possible MDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.
| Units on a scale | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12. | 10.97 ± 5.34 | 8.55 ± 4.74 |
BSID-II measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the psychomotor raw score which was used to calculate the PDI score. Possible PDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.
| Units on a scale | Genotropin® | Control |
|---|---|---|
| Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12. | 4.04 ± 3.04 | 8.55 ± 2.84 |
Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/ Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Month 3 (n = 21, 19) | -0.93 ± 1.217 | -1.37 ± 1.122 |
| Month 6 (n = 21, 19) | -1.20 ± 1.310 | -1.72 ± 1.077 |
| Month 12 (n = 20, 18) | -0.87 ± 1.330 | -1.84 ± 1.158 |
| Month 18 (n = 20, 19) | -0.56 ± 1.890 | -1.76 ± 1.153 |
| Month 24 (n = 20, 20) | -0.75 ± 1.384 | -1.65 ± 1.227 |
Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.
| SDS | Genotropin® | Control |
|---|---|---|
| Month 3 (n = 21, 19) | 0.27 ± 0.977 | 0.36 ± 0.693 |
| Month 6 (n = 21, 19) | -0.00 ± 0.423 | 0.07 ± 0.495 |
| Month 12 (n = 20, 18) | 0.26 ± 0.516 | 0.02 ± 0.587 |
| Month 18 (n = 20, 19) | 0.57 ± 1.094 | 0.04 ± 0.506 |
| Month 24 (n = 20, 20) | 0.39 ± 0.638 | 0.08 ± 0.602 |
Body weight was measured at all the relevant visits. The change from Baseline in body weight was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.
| Kg | Genotropin® | Control |
|---|---|---|
| Month 3 (n = 21, 19) | 0.57 ± 0.154 | 0.53 ± 0.406 |
| Month 6 (n = 21, 20) | 1.08 ± 0.269 | 1.01 ± 0.659 |
| Month 12 (n = 20, 19) | 2.34 ± 0.389 | 1.66 ± 0.397 |
| Month 18 (n = 20, 19) | 3.48 ± 0.669 | 2.41 ± 0.709 |
| Month 24 (n = 20, 20) | 4.79 ± 0.814 | 3.19 ± 0.601 |
Body mass index was calculated for all visits by means of the following formula: BMI (kg/m2) = Weight (kg)/(Height\[m\])2. The change from Baseline BMI was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.
| Kg/m2 | Genotropin® | Control |
|---|---|---|
| Month 3 (n = 21, 19) | -0.28 ± 0.419 | -0.05 ± 0.811 |
| Month 6 (n = 21, 20) | -0.57 ± 0.537 | 0.08 ± 1.013 |
| Month 12 (n = 20, 19) | -0.62 ± 0.650 | -0.29 ± 0.683 |
| Month 18 (n = 20, 19) | -0.78 ± 0.930 | -0.25 ± 0.806 |
| Month 24 (n = 20, 20) | -0.58 ± 0.823 | -0.55 ± 0.776 |
Collected over Up to the participant's age of 49 to 55 months (Follow-up visit). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotropin® | — | 6/21 (28.6%) | 21/21 (100%) |
| Control | — | 2/22 (9.1%) | 18/22 (81.8%) |
| Event | Genotropin® | Control |
|---|---|---|
| Conductive deafnessEar and labyrinth disorders | 2/21 | 0/22 |
| BronchopneumoniaInfections and infestations | 1/21 | 0/22 |
| GastroenteritisInfections and infestations | 1/21 | 1/22 |
| HordeolumInfections and infestations | 1/21 | 0/22 |
| Viral infectionInfections and infestations | 1/21 | 0/22 |
| ConcussionInjury, poisoning and procedural complications | 1/21 | 0/22 |
| DehydrationMetabolism and nutrition disorders | 1/21 | 0/22 |
| Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders | 1/21 | 0/22 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/21 | 0/22 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 1/21 | 0/22 |
| Event | Genotropin® | Control |
|---|---|---|
| PyrexiaGeneral disorders | 9/21 | 4/22 |
| NasopharyngitisInfections and infestations | 8/21 | 6/22 |
| Upper respiratory tract infectionInfections and infestations | 8/21 | 1/22 |
| BronchitisInfections and infestations | 6/21 | 6/22 |
| DiarrhoeaGastrointestinal disorders | 4/21 | 0/22 |
| VomitingGastrointestinal disorders | 4/21 | 4/22 |
| LaryngitisInfections and infestations | 4/21 | 0/22 |
| VaricellaInfections and infestations | 4/21 | 1/22 |
| ConjunctivitisEye disorders | 3/21 | 2/22 |
| Ear infectionInfections and infestations | 3/21 | 1/22 |
| Age, Continuous(Months) | Genotropin® | Control | Total |
|---|---|---|---|
| Mean | 24.91 ± 3.262 | 24.44 ± 3.324 | 24.67 ± 3.263 |
| Sex: Female, Male(Participants) | Genotropin® | Control | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 8 | 11 | 19 |
The record gives a start of Feb 2008, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone